Kun Peng International Ltd. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Kun Peng International Ltd. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $600.0K | Jul 13, 2023 |
| FY2022 | Sep 30, 2021 | $400.0K | Jul 13, 2023 |
| FY2020 | Sep 30, 2019 | $83.9K | Jan 13, 2021 |
| FY2019 | Sep 30, 2018 | $505.1K | Dec 30, 2019 |
| FY2018 | Sep 30, 2017 | $174.5K | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | $2.56M | Dec 21, 2017 |
| FY2016 | Sep 30, 2015 | $1.68M | Feb 27, 2017 |
| FY2015 | Sep 30, 2014 | $1.17M | Dec 28, 2015 |
| FY2014 | Sep 30, 2013 | $726.8K | Jan 12, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.44M | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | $2.08M | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | $3.92M | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | $7.51M | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | $5.59M | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | $819.1K | Feb 8, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $958.3K | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | $1.47M | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | $3.48M | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | $6.31M | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | $4.59M | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | $696.3K | Feb 8, 2022 |
| FY2020 | Sep 30, 2019 | $71.0K | Jan 13, 2021 |
| FY2019 | Sep 30, 2018 | $432.5K | Dec 30, 2019 |
| FY2018 | Sep 30, 2017 | $143.5K | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | $1.22M | Dec 21, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($1.26M) | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | ($1.97M) | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | ($2.15M) | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | ($1.83M) | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | ($1.61M) | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | ($208.8K) | Feb 8, 2022 |
| FY2020 | Sep 30, 2019 | ($206.7K) | Jan 13, 2021 |
| FY2019 | Sep 30, 2018 | ($548.4K) | Dec 30, 2019 |
| FY2018 | Sep 30, 2017 | ($745.5K) | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | ($247.3K) | Dec 21, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($1.78M) | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | ($2.00M) | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | ($2.25M) | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | ($2.01M) | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | ($1.78M) | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | ($208.9K) | Feb 8, 2022 |
| FY2020 | Sep 30, 2019 | ($279.0K) | Jan 13, 2021 |
| FY2019 | Sep 30, 2018 | ($634.2K) | Dec 30, 2019 |
| FY2018 | Sep 30, 2017 | ($598.4K) | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | ($225.2K) | Dec 21, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Sep 30, 2020 | $14.6K | Jan 13, 2021 |
| FY2020 | Sep 30, 2019 | $16.6K | Jan 13, 2021 |
| FY2019 | Sep 30, 2018 | $359.8K | Dec 30, 2019 |
| FY2018 | Sep 30, 2017 | $293.2K | Jan 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($208.2K) | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | $17.9K | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | ($427.0K) | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | ($1.59M) | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | $1.91M | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | $207.4K | Feb 8, 2022 |
| FY2020 | Sep 30, 2019 | ($151.5K) | Jan 13, 2021 |
| FY2019 | Sep 30, 2018 | ($657.1K) | Dec 30, 2019 |
| FY2018 | Sep 30, 2017 | ($571.6K) | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | ($121.9K) | Dec 21, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $320.5K | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | $139.2K | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | $19.3K | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | $70.7K | Feb 8, 2022 |
| FY2019 | Sep 30, 2018 | $8.5K | Dec 30, 2019 |
| FY2018 | Sep 30, 2017 | $101.5K | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | $2.6K | Dec 21, 2017 |
| FY2016 | Sep 30, 2015 | $1.8K | Feb 27, 2017 |
| FY2015 | Sep 30, 2014 | $3.1K | Dec 28, 2015 |
| FY2014 | Sep 30, 2013 | $2.4K | Jan 12, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $840.8K | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | $1.48M | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | $1.26M | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | $1.78M | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | $3.22M | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | $799.3K | Feb 8, 2022 |
| FY2020 | Sep 30, 2019 | $28.4K | Jan 13, 2021 |
| FY2019 | Sep 30, 2018 | $78.9K | Dec 30, 2019 |
| FY2018 | Sep 30, 2017 | $188.0K | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | $139.0K | Dec 21, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $9.03M | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | $8.67M | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | $6.28M | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | $5.44M | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | $5.24M | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | $1.01M | Feb 8, 2022 |
| FY2020 | Sep 30, 2019 | $609.9K | Jan 13, 2021 |
| FY2019 | Sep 30, 2018 | $506.0K | Dec 30, 2019 |
| FY2018 | Sep 30, 2017 | $985.8K | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | $855.3K | Dec 21, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($8.19M) | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | ($7.18M) | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | ($4.74M) | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | ($3.37M) | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | ($1.85M) | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | ($215.7K) | Feb 8, 2022 |
| FY2020 | Sep 30, 2019 | ($581.5K) | Jan 13, 2021 |
| FY2020 | Sep 30, 2018 | ($427.1K) | Jan 13, 2021 |
| FY2019 | Sep 30, 2017 | ($797.8K) | Dec 30, 2019 |
| FY2018 | Sep 30, 2016 | ($35.0K) | Jan 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($9.04M) | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | ($7.77M) | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | ($5.80M) | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | ($3.65M) | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | ($1.82M) | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | ($208.8K) | Feb 8, 2022 |
| FY2020 | Sep 30, 2019 | ($2.30M) | Jan 13, 2021 |
| FY2019 | Sep 30, 2018 | ($2.09M) | Dec 30, 2019 |
| FY2018 | Sep 30, 2017 | ($1.55M) | Jan 15, 2019 |
| FY2017 | Sep 30, 2016 | ($736.9K) | Dec 21, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $26.3K | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | $82.2K | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | $457.6K | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | $267.1K | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | $2.06M | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | $141.2K | Feb 8, 2022 |
| FY2020 | Sep 30, 2019 | $5.9K | Jan 13, 2021 |
| FY2020 | Sep 30, 2018 | $21.9K | Jan 13, 2021 |
| FY2019 | Sep 30, 2017 | $35.5K | Dec 30, 2019 |
| FY2018 | Sep 30, 2016 | $21.1K | Jan 15, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | 0 | Jul 13, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Jan 14, 2025 |
| FY2023 | Sep 30, 2022 | 0 | Jan 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 400.00M | Dec 31, 2025 |
| FY2025 | Sep 30, 2024 | 400.00M | Dec 31, 2025 |
| FY2024 | Sep 30, 2023 | 400.00M | Jan 14, 2025 |
| FY2025 | Oct 18, 2022 | 400.00M | Dec 31, 2025 |
| FY2023 | Sep 30, 2022 | 400.00M | Jan 16, 2024 |
| FY2022 | Sep 30, 2021 | 400.00M | Jul 13, 2023 |
| FY2021 | Sep 30, 2020 | 21.38M | Feb 8, 2022 |
| FY2020 | Sep 30, 2019 | 21.38M | Jan 13, 2021 |
| FY2019 | Sep 30, 2018 | 21.22M | Dec 30, 2019 |
| FY2018 | Sep 30, 2017 | 5.35M | Jan 15, 2019 |